Lopinavir-ritonavir, an antiviral drug combo used to treat HIV, was found to be "ineffective" in treating hospitalised COVID-19 patients, as per Oxford University's RECOVERY Trial. In total, 1,596 patients randomised to receive the drug were compared with 3,376 patients randomised to usual care alone. "The data convincingly rules out any meaningful mortality benefit," the Chief Investigators said.